Study to Assess the Effects of Intranasal... — Clinical Trial Details

Participants

Ages

18 – 65

Sexes

Male & Female

BMI

Psychosis History

Inclusion Criteria

Inclusion Criteria:
1. Males and non-pregnant females currently meeting the DSM-5 criteria for diagnosis of major depressive disorder (MDD), single episode or recurrent, with a current episode duration of 3 years or less (confirmed with the MINI);
2. episode has a Clinical Global Impressions Severity of Illness (CGI-S) score of at least 4 and a total score of at least 20 on the 17-item Hamilton Depression Rating Scale (HAMD17);
3. Age between 18-65;
4. HAMD17 total score of at least 20 and a decrease in score of 25% or less from that observed at the screening assessment;
5. Willing and able to provide informed consent;
6. History of failure to respond (<25% improvement) to at least one, but not more than four antidepressant trials in the current episode, or marked intolerance to antidepressants as demonstrated by four failed attempts to tolerate an adequate medication trial (lifetime).

Exclusion Criteria

Exclusion Criteria:
1. Unable to speak English well enough to participate in the rating scales which will only be provided in English.
2. Pregnancy or lactation.
3. Post-partum state (within 2 months of delivery).
4. History of substance abuse or dependence within the past year (except nicotine and caffeine).
5. A lifetime history of psychosis, bipolar disorder, or obsessive-compulsive disorder.
6. Diagnosis of posttraumatic stress disorder or an eating disorder in the past year.
7. Lack of response to a past adequate trial of electroconvulsive therapy (ECT) for MDD.
8. Prior treatment with TMS or a vagus nerve stimulator implant.
9. Use of hallucinogen in the last month.
10. Current treatment with any medication with NMDA receptor effects.
11. Any history of prior ketamine use.
12. Any clinically-significant medication or condition that would preclude the use of ketamine.
13. History of: a dissociative disorder, seasonal pattern of depression as defined by DSM-IV, any condition likely to be associated with increased intracranial pressure, space occupying lesion, seizure disorder except childhood febrile seizures, neurologic disorder or medication therapy known to alter seizure threshold, cerebrovascular accident, transient ischemic attack within the last 2 years, cerebral aneurysm, dementia, Parkinson's disease, Huntington's disease, multiple sclerosis, or a personality disorder (which in the judgement of the Investigator may hinder the patient in completing the procedures required by the study protocol).
14. Presence of ferromagnetic material in or in close proximity to the head.
15. Increased risk of seizure for any other reason, including prior diagnosis of increased intracranial pressure, pseudotumor cerebri, or history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes.
16. A true positive response to any question on the Transcranial Magnetic Stimulation Adult Safety Screen questionnaire.
17. Inability to locate and quantify a motor threshold as defined in the protocol.
18. ECT treatment within 3 months prior to the screening visit.
19. Use of any investigational drug within 4 weeks of the baseline visit.
20. Use of fluoxetine within 6 weeks of the baseline visit.
21. Use of an MAOI within 2 weeks of the baseline visit.
22. Use of any antidepressant within 1 week of the baseline visit.
23. Significant acute suicide risk, defined as follows: suicide attempt within the previous 6 months that required medical treatment; or greater than or equal to 2 suicide attempts in the past 12 months.
24. Has a clear-cut plan for suicide and states that he/she cannot guarantee that he/she will call his/her regular psychiatrist or the Investigator if the impulse to implement the plan becomes substantial during the study; or in the investigator's opinion, is likely to attempt suicide within the next 6 months.
25. Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease.
26. If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the rTMS trial.
27. Positive urine drug screen. (A positive urine drug screen at screening may be repeated once prior to randomization.)
28. Clinically significant laboratory abnormality on CBC, TSH, ECG or hepatic profile in the opinion of the Investigator.
29. Any known hypersensitivity or serious adverse effect with ketamine.
30. Any clinically-significant medication or condition that would preclude the use of ketamine including respiratory illness requiring the regular use of oxygen.

Company

Product

Legal

Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)

Detailed Description

Study Protocol

Preparation

Dosing

Integration

Study Arms & Interventions

Ketamine + rTMS

Interventions

Participants

Inclusion Criteria

Exclusion Criteria

Study Details

Study Team

Sponsors & Collaborators